Rachel Massicotte, PhD
The Metabolic Disorders and Complications (MeDiC) Program at the Research Institute of the McGill University Health Centre (RI-MUHC) integrates outstanding basic science, clinical and evaluative researchers who share the goal of developing new diagnostic tools, treatments and health policies for common and chronic metabolic disorders.
Obesity, diabetes and osteoporosis, along with their complications, including kidney failure, heart disease, fatty liver/cirrhosis, dementia and stroke, are diseases that together affect more than one in three Canadians.
The MeDiC Program unites basic, clinical, population health and outcomes research experts to tackle these problems across the lifespan in a multidisciplinary way, employing our state-of-the-art facilities at the Centre for Translational Biology, the Centre for Innovative Medicine and the Centre for Outcomes Research and Evaluation.
The Metabolic Disorders and Complications (MeDiC) Program is centered around five main research themes:
Review our research highlights and publications in the 2022 RI-MUHC Annual Report.
Researchers in the MeDiC program are involved in a multitude of research initiatives, including:
The Research Institute of the McGill University Health Centre (RI-MUHC) is a world-renowned biomedical and healthcare research centre. The Institute, which is affiliated with the Faculty of Medicine of McGill University, is the research arm of the McGill University Health Centre (MUHC) – an academic health centre located in Montreal, Canada, that has a mandate to focus on complex care within its community. The RI-MUHC supports over 460 researchers and close to 1,300 research trainees devoted to a broad spectrum of fundamental, clinical and health outcomes research at the Glen and the Montreal General Hospital sites of the MUHC.